Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

MSD Italia Srl, part of Merck & Co., Inc., is an Italian company located in Rome that manufactures pharmaceutical products. The firm was founded in 1891. Nicoletta Luppi has been the CEO since 2003.

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

Gritstone bio develops immunotherapies for cancer and infectious diseases. They started with tumor-specific neoantigens and their programs to include viral antigens displayed on the surface of the virally infected cells. Their biological immune system recognition of targets on the surface of abnormal cells is common to anti-tumor and anti-viral immunity. With the development and commercialization of immunotherapy drugs including checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer.

Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Chengdu Yuanrui Biotechnology Co., Ltd., established on 2013-07-03, Business scope includes biotechnology development,technical consulting,Technical Services,technology transfer;Sales:Chemical Products(Does not contain dangerous goods),cosmetic,Packaging Materials,Instrumentation,electronic product;Import and export of goods and technology;Conference and exhibition service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).Biological product production,Sales.(Did not obtain the relevant administrative license(approval),Do not carry out business activities).

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Jiaxing Anyu Biotechnology Co., Ltd., established on 2014-04-14, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Drug Wholesale;Veterinary drug production;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Genematrix is developing new diagnostic products for various diseases by developing a globally competitive core platform technologies in the field of molecular diagnostics, which is attracting attention as a high-technology in the line of biotechnology. The Molecular Diagnostic market has high growth rates among in-vitro diagnostics markets and is a high value-added industry that is highly dependent on advanced countries since global companies prevailed the most core technologies. Genematrix, since the beginning of the company, has developed its own technologies that is globally competitive in the field of molecular diagnostics through joint research with domestic and international companies and research institutes.

Changrui Biotechnology (Chengdu) Co., Ltd., established on 2021-09-30, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;Medical Research and Experimental Development;R&D and application of cell technology;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;Conference and Exhibition Services;New material technology research and development;New material technology promotion service;market survey(Does not include foreign investigations);marketing planning;Drug testing equipment sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Imaxio, a Lyon, and Saint Beauzire, France-based biopharmaceutical company specialized in the areas of vaccines and genomics

Chengdu Bo Pet Biotechnology Co., Ltd., established on 2017-07-19, Business scope includes general items:Research and development of bio-based materials technology;Import and export;Technology Import and Export;Research and development of biopesticide technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Bio-feed R&D;Feed Additive Sales;Pet Food and Supplies Wholesale;Pet food and supplies retail(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Veterinary drug business;Drug retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.